Comparative Study Between Oral Azathioprine and Intravenous Cyclophosphamide Pulses in the Treatment of Idiopathic Pulmonary Fibrosis;Estudio comparativo entre azatioprina oral y pulsos intravenosos de ciclofosfamida en el tratamiento de la fibrosis pulmonar idiopática

Archivos de Bronconeumologia

Volumn 46, Issue 1, 2010, Pages 15-19

  Roig, Vicente ^a   Herrero, Águeda ^a   Arroyo Cózar, Marta ^a   Vielba, David ^a   Juarros, Santiago ^a   Macías, Enrique ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

Author keywords

Idiopathic pulmonary fibrosis; Immunosuppressants; Intravenous cyclophosphamide pulses; Oral azathioprine; Treatment

Indexed keywords

AZATHIOPRINE; CARBON MONOXIDE; CYCLOPHOSPHAMIDE; PREDNISONE;

ADULT; AGED; ARTERIAL OXYGEN TENSION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; HUMAN; LEUKOPENIA; LIVER TOXICITY; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; LUNG GAS EXCHANGE; LUNG TOXICITY; LUNG TRANSPLANTATION; MALE; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT DISEASE; COMBINATION DRUG THERAPY; DRUG SAFETY; FORCED VITAL CAPACITY; MIGRAINE; MONOTHERAPY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; SINGLE DRUG DOSE; SPINE FRACTURE; UTERINE CERVIX CARCINOMA IN SITU;

ADMINISTRATION, ORAL; ADULT; AGED; AZATHIOPRINE; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY FIBROSIS; PULSE THERAPY, DRUG;

EID: 73149122746     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbres.2009.09.015     Document Type: Article

References (21)

1. Panos R.J., Mortenson R., Niccoli S.A., and King Jr. T.E. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 88 (1990) 396-404
2. Schwartz D.A., Helmers R.A., Galvin J.R., Van Fossen D.S., Frees K.L., Dayton C.S., et al. Determinants of survival in idiopathic pulmonary fibrosis. Am J. Respir Crit Care Med 149 (1994) 450-454
3. Flaherty K.R., Toews G.B., Travis W.D., Colby T.V., Kazerooni E.A., Gross B.H., et al. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 19 (2002) 275-283
4. Idiopathic pulmonary fibrosis: diagnosis and treatment international consensus statement. Am J Respir Crit Care Med 161 (2000) 646-664
5. Xaubet A., Ancochea J., Blanquer R., Montero C., Morell F., Rodríguez Becerra E., et al. Diagnóstico y tratamiento de las enfermedades pulmonares intersticiales difusas. Arch Bronconeumol 39 (2003) 580-600
6. Johnson M.A., Kwan S., Snell N.J., Nunn A.J., Darbyshire J.H., and Turner-Warwick M. Randomized controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 44 (1989) 280-288
7. Raghu G.W., Depaso W.J., Cain J., Hammar S.P., Wetzel C.E., Dreis D.F., et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective, double-blind randomized, placebo-controlled clinical trial. Am Rev Respir Dis 144 (1991) 291-296
8. Collard H.R., Ryu J.H., Douglas W.W., Schwarz M.I., Rurran-Everett D., King T.E., et al. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest 125 (2004) 2169-2174
9. Davies HR, Richeldi L, Walters EH. Agentes inmunomoduladores para la fibrosis pulmonar idiopática (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus. 2008(4). Oxford: Update Software Ltd. Disponible en: http://www.update-software.com
10. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 165 (2002) 277-304
11. Walter N., Harold R., Collard R., and King T.E. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc 3 (2006) 330-338
12. Langford C.A. Management of systemic vasculitis. Best Pract Res Clin Rheumatol 15 (2001) 281-297
13. Lynch III J.P., and McCune W.J. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med 155 (1997) 395-420
14. McCune W.J., Golbus J., Zeldes W., Bohlke P., Dunne R., and Fox D.A. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 318 (1988) 1423-1431
15. Baughman R.P., and Lower E.E. Use of intermittent intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Chest 102 (1992) 1090-1094
16. Kolb M., Kirschner J., Riedel W., Wirtz H., and Schmidt M. Cyclophosphamide pulse therapy in idiopathic pulmonary fibrosis. Eur Respir J 12 (1998) 1409-1414
17. Pereira C.A.C., Malheiros T., and Coletta E.M. Survival in idiopathic pulmonary fibrosis-cytotoxic agentes compared to corticosteroids. Repir Med 100 (2006) 340-347
18. Selman M., Navarro C., and Gaxiola M. Fibrosis pulmonar idiopática: en busca de un tratamiento eficaz. Arch Bronconeumol 41 (2005) 15-20
19. Nagai S., Hamada K., Shigematsu M., Taniyama M., Yamauchi S., and Izumi T. Open label compassionate use one year treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 41 (2002) 1118-1123
20. Ancoechea J., Antón E., and Casanova A. Nuevas estrategias terapéuticas en fibrosis pulmonar idiopática. Arch Bronconeumol 40 (2004) 16-22
21. Demedts M., Behr J., Buhl R., Costabel U., Dekhuijzen R., Jansen H.M., et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 353 (2005) 2229-2242